AMPG vs EXFY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
AMPG's deterministic health scores signal severe financial distress: the Piotroski F-Score of 1/9 indicates extreme weakness in operational and financial health, while the absence of an Altman Z-Score raises unquantified bankruptcy risk. Despite a remarkable 115% YoY revenue growth and a recent positive earnings surprise, the company operates at a significant loss with negative ROE (-27.13%) and ROA (-13.23%), and its gross margin (23.07%) is insufficient to offset deep operating and net losses. The stock trades at a premium valuation (P/S of 2.86, forward P/E of 4.74) despite negative profitability, suggesting high growth expectations that may not be sustainable. Analysts' target price of $9.00 reflects optimism, but with only one analyst covering the stock and no insider buying, conviction remains low.
EXFY shows bearish fundamentals based on deterministic rules. Financial strength is weak (F-Score 2/9). Concerns include weak profitability or high valuation.
Compare Another Pair
Related Comparisons
AMPG vs EXFY: Head-to-Head Comparison
This page compares AmpliTech Group, Inc. (AMPG) and Expensify, Inc. (EXFY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.